Nanomachines aim to deliver cancer drugs to hard-to-reach areas like the brain
Credit: © 2019 Kanjiro Miyata
In a recent study in mice, researchers found a way to deliver specific drugs to parts of the body that are exceptionally difficult to access. Their Y-shaped block catiomer (YBC) binds with certain therapeutic materials forming a package 18 nanometers wide. The package is less than one-fifth the size of those produced in previous studies, so can pass through much smaller gaps. This allows YBCs to slip through tight barriers in cancers of the brain or pancreas.
The fight against cancer is fought on many fronts. One promising field is gene therapy, which targets genetic causes of diseases to reduce their effect. The idea is to inject a nucleic acid-based drug into the bloodstream – typically small interfering RNA (siRNA) – which binds to a specific problem-causing gene and deactivates it. However, siRNA is very fragile and needs to be protected within a nanoparticle or it breaks down before reaching its target.
“siRNA can switch off specific gene expressions that may cause harm. They are the next generation of biopharmaceuticals that could treat various intractable diseases, including cancer,” explained Associate Professor Kanjiro Miyata of the University of Tokyo, who jointly supervised the study. “However, siRNA is easily eliminated from the body by enzymatic degradation or excretion. Clearly a new delivery method was called for.”
Presently, nanoparticles are about 100 nanometers wide, one-thousandth the thickness of paper. This is small enough to grant them access to the liver through the leaky blood vessel wall. However some cancers are harder to reach. Pancreatic cancer is surrounded by fibrous tissues and cancers in the brain by tightly connected vascular cells. In both cases the gaps available are much smaller than 100 nanometers. Miyata and colleagues created an siRNA carrier small enough to slip through these gaps in the tissues.
“We used polymers to fabricate a small and stable nanomachine for the delivery of siRNA drugs to cancer tissues with a tight access barrier,” said Miyata. “The shape and length of component polymers is precisely adjusted to bind to specific siRNAs, so it is configurable.”
The team’s nanomachine is called a Y-shaped block catiomer, as two component molecules of polymeric materials are connected in a Y-shape formation. The YBC has several sites of positive charge which bind to negative charges in siRNA. The number of positive charges in YBC can be controlled to determine which kind of siRNA it binds with. When YBC and siRNA are bound, they are called a unit polyion complex (uPIC), which are under 20 nanometers in size.
“The most surprising thing about our creation is that the component polymers are so simple, yet uPIC is so stable,” concluded Miyata. “It has been a great but worthy challenge over many years to develop efficient delivery systems for nucleic acid drugs. It is early days, but I hope to see this research progress from mice to help treat people with hard-to-treat cancers one day.”
Sumiyo Watanabe, Hyun Jin Kim, Hiroyuki Chaya, Satoshi Uchida, Satomi Ogura, Horacio Cabral, Yu Matsumoto, Hiroshi Fukuhara, Masaomi Nangaku, Kensuke Osada, Kanjiro Miyata, Kazunori Kataoka, et al. In vivo rendezvous of small nucleic acid drugs with charge-matched block catiomers to target cancers. Nature Communications. DOI: 10.1038/s41467-019-09856-w
Funding Program for World-Leading Innovative R&D in Science and Technology (FIRST) from JSPS. Center of Innovation (COI) Program from JST. JSPS KAKENHI Grants 24659411, 25000006, 25282141 and 17H02098. Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) from AMED. Project for Cancer Research and Therapeutic Evolution (P-CREATE) from AMED. Basic Science and Platform Technology Program for Innovative Biological Medicine (IBIOMED) from AMED.
Department of Materials Engineering
Graduate School of Engineering
Associate Professor Kanjiro Miyata
Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656, JAPAN
Email: [email protected]t.u-tokyo.ac.jp
Mr. Rohan Mehra
Division for Strategic Public Relations, The University of Tokyo
7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654, JAPAN
Email: [email protected]
About the University of Tokyo
The University of Tokyo is Japan’s leading university and one of the world’s top research universities. The vast research output of some 6,000 researchers is published in the world’s top journals across the arts and sciences. Our vibrant student body of around 15,000 undergraduate and 15,000 graduate students includes over 2,000 international students. Find out more at https:/
Related Journal Article